IHC - diagnostic panel for Lung cancer

The IHC panel for lung cancer is designed to confirm the diagnosis of lung cancer and differentiate its subtypes. The information obtained from this test helps guide the most appropriate treatment options.

No, fasting is not required for this test. The test is performed on a tissue sample obtained via a biopsy procedure.

The sample is usually collected through a biopsy of the lung tissue. Your healthcare provider will give you specific instructions based on the biopsy procedure type.

Each marker has specific significance. For instance, Napsin A and TTF1 are often positive in adenocarcinomas of lung origin. CK7 and CK20 can help differentiate lung cancer from other cancers. P63 and CK 5/6 are typically seen in squamous cell carcinoma. CD56, Synapto, and Chromogranin are markers for neuroendocrine tumors.

The turnaround time is typically 5-7 days but may vary based on the laboratory.

There is no specific preparation required for this test. However, because a biopsy is involved, your healthcare provider will give you instructions based on your overall health and the specific biopsy procedure.

This test is done when lung cancer is suspected based on clinical symptoms, imaging studies, and other preliminary tests.

The IHC panel for lung cancer provides crucial information about the type and subtype of the lung cancer, which influences the treatment options and prognosis.

This test is typically performed once for diagnosis. However, if treatment is given and then symptoms reappear, the test may be repeated to assess for recurrence or metastasis.

In normal lung tissue, there is a specific pattern of marker expression. Significant deviation from this pattern, such as the increased expression of certain markers, can indicate lung cancer.

The primary precaution is related to the biopsy procedure, as it carries a risk of complications such as bleeding or infection. Your healthcare provider will discuss these risks with you and give you specific instructions to minimize them.

Non-modifiable factors include genetic predisposition to lung cancer. Modifiable factors are limited, as these markers are specific to the cells and not influenced by environmental or lifestyle factors.

If results are abnormal, you should consult with your oncologist or pulmonologist. They can interpret the results and guide the next steps in your care.

Additional tests might include PET/CT scans, molecular testing for genetic mutations, and other blood tests to assess your overall health and organ function.

The results are generally very reliable but should be interpreted in conjunction with your medical history, symptoms, and other diagnostic findings.

In conclusion, the IHC diagnostic panel for lung cancer is a vital tool in diagnosing and differentiating lung cancer subtypes. These findings can significantly influence the treatment course and potentially affect the prognosis. As with all medical procedures and tests, it is essential to discuss the results and implications thoroughly with your healthcare provider.